FDA Approves First New Non-Opiod Painkiller in Decades
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
US FDA approves Vertex's non-opioid painkiller
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Truist Financial Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
Truist Financial analyst Joon Lee maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s shares closed ...
Pharmaceutical Technology4h
FDA approves Vertex’s acute pain treatment Journavx
The FDA has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults with moderate-to-severe acute pain.
FiercePharma11h
Vertex scores FDA nod for long-awaited non-opioid pain reliever Journavx
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...